Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia

Publisher： Karger

E-ISSN： 1662-6575|9|2|373-378

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.2, 2016-06, pp. : 373-378

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 3, 2015-03 ,pp. : 338-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 62-66

Karger

Access to resources Recommend Favorite

Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient

By  

Oncology Research and Treatment, Vol. 40, Iss. 10, 2017-09 ,pp. : 621-622

Karger

Access to resources Recommend Favorite

Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy

By  

Case Reports in Oncology, Vol. 9, Iss. 3, 2016-11 ,pp. : 691-697

Karger

Access to resources Recommend Favorite

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 4, 2018-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite